Clinical Trials Logo
  1. Home
  2. Brain Tumor - Metastatic
  3. NCT05831631

Characterization of Circulating and Tumor-infiltrating Immune Cells in Malignant Brain Tumors

Brain Tumor, Primary Clinical Trial

Official title:
Immunophenotype Characterization of Circulating and Tumor Infiltrating Immune Cells in Malignant Brain Tumors.

Clinical Trial Summary

The goal of this observational study is to characterize the circulating leukocyte profile and the immune T cells distribution within the tumor in patients with malignant brain tumors and to correlate these findings with the oncological outcome. Participants will be subjected to blood sampling before surgery and for 12 months of follow-up. Additional sampling and analysis will be performed on tumor samples.

Clinical Trial Description

High-grade gliomas are the most frequent type of primary brain tumor in adults, and among them, glioblastoma multiforme (GBM) is the most malignant with an associated poor prognosis. Although significant advances have been achieved in GBM biology comprehension, patients' life expectancy is still limited to 18 months. Brain metastases (BM) are the most frequent neoplasm in the CNS; it is estimated that up to 14% of all newly diagnosed cancers will soon or later metastasize into the brain. A variety of mechanisms to escape a tumor-specific T cell-mediated immune response have been identified in glioma and other cancer entities. This project is an observational, prospective, monocentric study on patients candidates for neurosurgical procedures for brain malignant tumors with additional collection of biological material. With the present study, we aim to characterize the phenotype of both circulating- and tumor-infiltrating- immune cells at the diagnosis and their changes during disease progression and after treatment in primary and secondary brain tumors. Samples will be taken at baseline (before surgery) and at time-points: 3, 6, 9, 12 months ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05831631
Study type Observational
Source IRCCS San Raffaele
Contact Laura Sincinelli
Phone 0226435568
Email sincinelli.laura@hsr.it
Status Recruiting
Phase
Start date August 1, 2022
Completion date August 1, 2025
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT06057168 - Performance of Elucirem® in DSC-MRI Perfusion of Brain Gliomas Phase 3
Recruiting NCT04427384 - Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)
Completed NCT03323450 - Cognitive Remediation Therapy for Brain Tumor Patients: Improving Working Memory N/A
Completed NCT00241670 - Fluorescence-guided Resection of Malignant Gliomas With 5-Aminolevulinic Acid Phase 3
Not yet recruiting NCT01445691 - More Complete Removal of Malignant Brain Tumors by Fluorescence-Guided Surgery Phase 2
Completed NCT02599142 - Comparing Immobilisation Shells in Cranial Radiotherapy N/A
Recruiting NCT06282562 - FeelFit: High-intensity Interval Training to Improve Self-reported Physical Fitness in Brain Tumor Patients N/A
Recruiting NCT06322342 - Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent Phase 2
Completed NCT00001574 - A Pilot Study of 1H-Nuclear Magnetic Resonance Spectroscopic Imaging in Pediatric Patients With Primary and Metastatic Brain Tumors
Completed NCT04365647 - Intra-operative Variation in Size of Brain Tumors After Craniotomy
Not yet recruiting NCT06185686 - Radiation Induced Alterations in Resting State Brain Networks in Pediatric Brain Tumor Patients
Withdrawn NCT04776980 - Multimodality MRI and Liquid Biopsy in GBM Early Phase 1
Completed NCT03262636 - Two-Part Study to Evaluate the Safety and Efficacy of Image Guided Surgery Using Indocyanine Green for Intramolecular Imaging of Nervous System Tumors Compared to Standard of Care, (TumorGlow) Phase 1
Active, not recruiting NCT02006407 - A Pilot Study to Evaluate Neurocognitive Injury and Longitudinal Changes in White Matter During Radiation Therapy in Children With Primary Brain Tumors N/A
Recruiting NCT03213002 - Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM Phase 1/Phase 2
Recruiting NCT05775458 - Glutamate Excitotoxicity and Its Role in Glioblastoma Biology
Terminated NCT04901806 - Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors Phase 1
Recruiting NCT03373487 - Cognitive Rehabilitation in Brain Tumor Patients After Neurosurgery N/A
Not yet recruiting NCT06106997 - Clinical Feasibility of Brain Radiotherapy Using Synthetic CTs in an MRI-only Workflow N/A
Recruiting NCT05254197 - SeOuL cOhort of Brain Tumor MONitoring Study (SOLOMON)